Back to search
FDAFDA · Food and drugs·Recall number D-0486-2026

Furosemide Tablets, USP, 80 mg, 100 Tablets bottles, Rx only, Manufactured by: Leading Pharma, LLC, Fairfield, NJ 07004, NDC 69315-118-01

Published April 29, 2026 · Recall initiated: March 20, 2026

Summary

FDA records drug Class II recall D-0486-2026, published April 29, 2026 and initiated March 20, 2026. Recalling firm: Leading Pharma, LLC; Status: Ongoing; Reported quantity: 9384 bottles; Lot: Lots# H03125, H03225, H03325, Exp Date: 2027/08. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations; presence of N-nitroso-Furosemide (NNF) above the recommended intake limit.

What to do

Voluntary: Firm initiated · Letter

Get an email if FUROSEMIDE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
FUROSEMIDE
Manufacturer
Leading Pharma, LLC
Distributor
US Nationwide.
Lot
Lots# H03125, H03225, H03325, Exp Date: 2027/08
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Furosemide Tablets, USP, 80 mg, 100 Tablets bottles, Rx only, Manufactured by: Leading Pharma, LLC, Fairfield, NJ 07004, NDC 69315-118-01 recalled?

Yes. FDA published recall D-0486-2026 on April 29, 2026. Reported hazard: CGMP Deviations; presence of N-nitroso-Furosemide (NNF) above the recommended intake limit.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: FUROSEMIDE.